, Tracking Stock Market Picks
Enter Symbol:
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

up 220.27 %

Regeneron Pharmaceuticals, Inc. (REGN) rated Overweight with price target $305 by Barclays

Posted on: Monday,  May 6, 2013  1:25 PM ET by Barclays

Barclays rated Overweight Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 05/06/2013. Previously Barclays rated Overweight Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 02/28/2013.,
when the stock price was $167.98. Since then, Regeneron Pharmaceuticals, Inc. has gained 220.28% as of 01/27/2016's recent price of $538.00.
If you would have followed the previous Barclays's recommendation on REGN, you would have gained 220.27% of your investment in 1063 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/6/2013 1:25 PM Buy
262.85 305.00
as of 12/13/2013
1 Week down  -4.65 %
1 Month down  -2.74 %
3 Months down  -7.02 %
1 YTD up  2.56 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/2/2013 1:25 PM Buy
248.39 275.00
2/28/2013 2:25 PM Buy
167.98 194.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy